Next Article in Journal
Comparison of Baerveldt 101-350 Glaucoma Implant (BGI) versus Trabeculectomy with ExPress™ Shunt for the Treatment of Primary Open Angle Glaucoma
Next Article in Special Issue
CD40, a Novel Inducer of Purinergic Signaling: Implications to the Pathogenesis of Experimental Diabetic Retinopathy
Previous Article in Journal
If not When, then Where? Ignoring Temporal Information Eliminates Reflexive but not Volitional Spatial Orienting
Previous Article in Special Issue
Targeting the P2X7 Receptor in Age-Related Macular Degeneration
Article Menu

Export Article

Open AccessReview
Vision 2017, 1(2), 14; doi:10.3390/vision1020014

The Role of the P2X7 Receptor in Ocular Stresses: A Potential Therapeutic Target

1
UMR 8638 CNRS COMETE, Université Paris Descartes, Sorbonne Paris Cité, Faculté de Pharmacie, 4 Avenue de l’Observatoire, 75006 Paris, France
2
Recherche et Développement, Laboratoire d’Evaluation Physiologique, Yslab, 2 rue Félix Le Dantec, 29000 Quimper, France
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editors: Tetsuya Sugiyama and Andrew Parker
Received: 28 February 2017 / Revised: 10 April 2017 / Accepted: 14 May 2017 / Published: 17 May 2017
(This article belongs to the Special Issue Purinergic Receptors in the Eye)
View Full-Text   |   Download PDF [253 KB, uploaded 17 May 2017]   |  

Abstract

The P2X7 receptor is expressed in both anterior and posterior segments of the eyeball. In the ocular surface, the P2X7 receptor is activated in case of external aggressions: preservatives and surfactants induce the activation of P2X7 receptors, leading to either apoptosis, inflammation, or cell proliferation. In the retina, the key endogenous actors of age-related macular degeneration, diabetic retinopathy, and glaucoma act through P2X7 receptors’ activation and/or upregulation of P2X7 receptors’ expression. Different therapeutic strategies aimed at the P2X7 receptor exist. P2X7 receptor antagonists, such as divalent cations and Brilliant Blue G (BBG) could be used to target either the ocular surface or the retina, as long as polyunsaturated fatty acids may exert their effects through the disruption of plasma membrane lipid rafts or saffron that reduces the response evoked by P2X7 receptor stimulation. Treatments against P2X7 receptor activation are proposed by using either eye drops or food supplements. View Full-Text
Keywords: ocular; stress; P2X7 receptor; modulation; therapeutic target ocular; stress; P2X7 receptor; modulation; therapeutic target
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Dutot, M.; Olivier, E.; Wakx, A.; Rat, P. The Role of the P2X7 Receptor in Ocular Stresses: A Potential Therapeutic Target. Vision 2017, 1, 14.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Vision EISSN 2411-5150 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top